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ABSTRACT
The potential for neuroprotection by baicalein (5,6,7-trihydroxyflavone), a major constituent from the root of a widely used
Chinese medicinal herb Scutellaria baicalensis Georgi, against methamphetamine-induced neurotoxicity was studied. All ICR mice
were treated by 4-times repeated intraperitoneal administration, at 2 hr intervals, of either methamphetamine (5 mg/kg), saline,
baicalein (1 mg/kg) or baicalein pretreatment followed by methamphetamine. In the striatum of mouse, the tissue level of dopamine
was monitored on day 3 and nitric oxide was assayed after 1 hr, 24 hrs and 3 days of the above treatments. The results showed that
striatal dopamine was significantly depleted by methamphetamine and elevated by baicalein. Pretreatment with baicalein prevented
the methamphetamine-induced dopamine depletion. Nitric oxide was depressed by methamphetamine, elevated by baicalein, but
remained suppressed with baicalein plus methamphetamine after 1 hr post-treatment. At 24 hrs nitric oxide concentration was
unaffected by methamphetamine but was significantly elevated by baicalein or baicalein plus methamphetamine administration.
On 3 days post-treatment nitric oxide was elevated by methamphetamine, baicalein and further markedly elevated by the administration of baicalein plus methamphetamine. These results suggest a potential neuroprotective role for baicalein with the possible
involvement of nitric oxide.
Key words: Baicalein, Methamphetamine, Dopamine, Nitric oxide

INTRODUCTION
The toxic effects of methamphetamine (METH)
specified on monoamine systems are partly involved in
the acute and long-term depletion on dopamine (DA) and
serotonin in striatal nerve terminals (1-2). Recent studies
have demostrated that chronic use of METH damages DA
fibers and leads to a prolonged functional changes. These
changes are including the decreases of DA transporter
numbers and tyrosine hydroxylase activity as well as the
releases of DA which in turn interacts with the previous two factors in striatum(3-8). Neurotoxicity caused by
repeated administration of high dose of METH (5 mg/kg,
i.p., × 4, 2 hr intervals) has heavily reported. However,
the pathways involved in the METH-induced neurodegeneration were not clear.
Current views indicated that the major mechanisms
responsible for long-lasting toxic effects of METH are
associated with DA and glutamate eff lux(9-11). Studies
also support the hypothesis that METH-induced dopaminergic neurotoxicity is related with the formation of free
radicals(12-13). Following the auto-oxidation process, the
concentrations of superoxide radical, hydrogen perox* Author for correspondence. Tel: +886-2-28267094;
Fax: +886-2-28264372

ide and hydroxyl radicals then heavily raised (10,14). On
the other hand, METH also promotes the generation of
peroxynitrite, a neurotoxin produced from the interaction
of nitric oxide (NO) and superoxide radical. Peroxynitrite
has potentials for the lipid peroxidation which is linked to
neuronal degeneration.
NO is a general free radical gas that exerts both
neurotoxic and neuroprotective effects (15-18) . Previous studies have suggested that N-Methyl-D-aspartate
(NMDA) glutamate receptor activation-induced elevation of nitric oxide synthase (NOS) activity is mainly
responsible for the NMDA-dependent neurotoxicity as
it is preventable by NOS inhibitors. For instance, high
dose of Nω-nitro-L-arginine methyl ester (L-NAME, 30
mg/kg, i.p., × 2), significantly reduced the METH-induced
DA depletion in the striatum (19). However, NO-donor,
3-morpholino-sydnonimine (SIN-1) has also been shown
to be neuroprotective in a cerebral ischemia rat model(20).
Baicalein, one of the major flavonoids in the dry root
of Scutellaria baicalensis Georgi, is widely used in traditional Chinese medicine (21). It has a variety of biological activities such as anti-bacterial, anti-inf lammatory,
antioxidant, antithrombotic and antitumor properties. In
1999, Chen et al. found that baicalein inhibited the endothelium/NO-mediated relaxation at low concentrations
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(0.3-10 μM) and relaxed the endothelium-denuded vessels
at higher concentrations (30-300 μM) (22). Furthermore,
Lee et al. reported that baicalein exhibited significant
protective effects on central neurons against glutamateinduced and glucose deprivation-induced neuronal death
in 2003(23). Such findings prompted the present attempt
to investigate the effects of baicalein on METH-induced
neuronal toxicity and the possible role of NO.

MATERIALS AND METHODS
I. Animals
Male ICR mice 4-5 weeks old, were obtained from
Laboratory Animal Center, National Taiwan University
College of Medicine. Mice were housed in the environmentally controlled quarters with a 12-hour light/dark
lighting cycle and constant room temperature at 23 ± 1°C.
Food and water were given ad libitum.
II. Drugs
Methamphetamine hydrochloride was purchased
from National Bureau of Controlled Drugs, Department
of Health, Taiwan, R.O.C. Baicalein was purchased from
Sigma Chemical Co. (98%, Aldrich, US).
III. Animal Models of METH-induced Neurotoxicity
Animals were divided into four groups (n = 9 per
group). Animals in Groups I & II received four intraperitoneal injections of saline or baicalein (1 mg/kg) at 2 hr
intervals. Groups III & IV animals were pretreated with
saline or baicalein (1 mg/kg, i.p.) 30 mins before each
METH (5 mg/kg, i.p., × 4, 2 hr intervals). The mice were
sacrificed 3 days after the last injection, and the striatal
tissues were sliced from both hemispheres for the determination of DA levels. In addition, NO concentrations were
determined one hr, 24 hrs and 3 days post treatment.
IV. Dopamine Levels
The concentrations of DA in striatal tissues were
quantified by a modified high performance liquid chromatography (HPLC) method combined with electrochemical
(EC) detection (24). Striatal tissue was homogenized in
600 μL of DA mobile phase solution consisting of 75 nM
sodium dihydrogen phosphate, 1.5 nM sodium dodecyl
sulfate, 0.72 mM triethylamine, 200 μM EDTA, 12%
methanol and 13.5% acetonitrile (pH 4.0), and centrifuged
at 4°C (1 × 104 rpm, 4 min). Three hundred microlitres of
the supernatant was then removed and filtered through a
0.2 μm Nylon-66 microfilter. Following a 10-fold dilution,
aliquot of 20 μL from each sample was injected into the
HPLC/EC system for DA assay. The amount of DA was
determined using standard curves that were generated by

determining in triplicates the responses of three known
standards. Protein determinations were performed by the
Lowry method(25).
V. Determination of Nitric Oxide
Brains of mice were rapidly removed and placed on
ice. The striatums were quickly removed and homogenized at 0°C in 300 μL of 3D water that had been
degassed 15 min before. The homogenate was then centrifuged at 1 × 104 rpm for 10 min at 4°C. The supernatants
were divided into two parts for NO assay and for protein
determination. For NO determination, the samples were
deproteinized by adding 100% ethanol (volume 1:1) and
then centrifuged at 1.4 × 10 4 rpm for 10 min at 4°C. To
avoid possible changes due to postmortem or storage, a 50
μL aliquot of the supernatant was immediately detected
by the NO/ozone chemiluminescence technique using
NO-Analyzer (Model 280, Sievers Co. Ltd.). This method
measures the oxidation form of NO (nitrate) with a powerful reaction agent (0.1 M vanadium chloride, Merck,
Darmstadt, Germany) dissolved in 8% HCl solution.
Sample was purged by a stream of helium (99%) from the
reaction vessel to the chemiluminescence chamber. The
reactions were measured and transformed into electrical
signals by the photomultiplier tube. Fresh NaNO3 solution
(100 mM in 3D water) was used for the standard curve,
which was made by triple injections of each concentration
(10, 100, 500, or 1000 nM NO).
VI. Statistical Analysis
All data in these experiments are presented as mean
± SEM. The SPSS (Statistical Package for the Social
Science), version 11.0 was used for the statistical analysis. One-way ANOVA was performed to determine the
differences between groups, and furthermore post-hoc
comparisons between means were made by Tukey test.
The significant levels were defined at p < 0.05.

RESULTS
The levels of DA formation in striatum of mice 3
days after the last injection were shown in Figure 1. In
this experiment, it was found that baicalein reversed the
neurotoxicity of METH. Repeated injections of METH
(5 mg/kg, i.p., × 4, 2 hr intervals) significantly decreased
the contents of DA in striatal tissues as compared with
saline-treated mice (F = 38.657, p < 0.05). In addition,
mice treated with baicalein (1 mg/kg, i.p., × 4) showed an
increase of DA concentration in striatum after treatment
as compared with SS (F = 38.657, p < 0.05). In the group
of baicalein + METH (BM), it significantly reversed DA
level in striatal tissues (F = 38.657, p < 0.05, compared
with SM mice) and attenuated METH toxic effects on
dopaminergic system.
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with SS) measured 3 days after the last injection. Therefore, the synergistic enhancing effects of METH and baicalein resulted in a large increase of NO in the BM group.
Together, these findings indicate that baicalein persis-
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Figure 1. Mice striatal dopamine levels at 3 days post-treatment.
Animals were injected introperitoneally 4 times at 2 hrs intervals
with saline (SS), saline + 4 × METH (SM), baicalein + 4 × saline
(BS) and baicalein + 4 × METH (BM). Results are shown as mean ±
S.E.M. DA level was significantly depressed by 5 mg/kg METH (in
SM), and elevated by 1 mg/kg baicalein (in BS) (*P < 0.05, vs. SS).
Baicalein pretreatment prevented the METH-induced DA depression
(+P < 0.05 vs. SM).
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The tissue levels of NO collected one hour after mice
exposed to a toxic dose regimen of METH (5 mg/kg, i.p.,
× 4, 2 hr intervals) were shown in Figure 2A. There was
a significant decrease in striatal NO concentrations in the
SM group as compared with SS (F = 46.372, p < 0.001).
The mice that received baicalein before saline injection
(BS) showed a significant increase in NO levels (F =
46.372, p < 0.001, compared with SS). The NO concentration decreased dramatically in BM group. It was due to
that the enhancing effect of baicalein was unable to overcome the suppressing effects of METH, resulting in an
overall decrease in striatal NO.
The formation of NO in the mice striatum over a
period of 24 hrs after the last injection was shown in
Figure 2B. In SM mice, it was observed that NO, significantly reduced 1 hr after the last injection, had returned
to a level similar to that of the control after 24 hrs. On
the other hand, in mice treated with baicalein and saline
(BS), NO formation was still enhanced at the similar level
as compared to the 1hr data. Since the suppressing effect
of METH was diminished and the enhancing effect of
baicalein remained the same, the NO of BM group was
therefore in a net increase. Both BS and BM groups were
significantly different from control (F = 22.450, p < 0.05,
compared with SS). In addition, there were no significant
difference in NO concentrations between BM and BS mice.
As depicted in Fig ure 2C, METH signif icantly
increased NO productions in the striatum after 3 days
(F = 60.893, p < 0.001, SM compared with SS). Again,
mice treated with baicalein and saline still exhibited an
increased level of NO (F = 60.893, p < 0.001, BS compared

Figure 2. The Nitric oxide levels in mice striatum after drug
treatments. Mice were injected introperitoneally 4 times at 2 hrs
intervals with saline (SS), saline + 4 × METH (SM), baicalein + 4
× saline (BS) and baicalein + 4 × METH (BM). Results are shown
as mean ± S.E.M. NO level was significantly depressed by METH
(5 mg/kg) which elevated by baicalein (1 mg/kg) and depressed by
baicalein + METH at 1 hr post-treatment [A]; NO concentrations in
both BS and BM groups were significantly elevated at 24 hrs posttreatment [B]; and it was significantly elevated either by METH
or baicalein, furthermore it increased more higher by baicalein +
METH in 3 days post-treatment [C]. *P < 0.0001 vs. SS and +P <
0.0001 vs. SM and BS.
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tently kept elevated striatal NO concentrations up to 3
days after treatment. However, administration of four
injections of METH caused a short-term decrease in NO
formation in one hour; NO level returned to the normal at
24 hrs after last injection, and then reached a significant
peak that will last to the end of the experiment (3 days).

DISCUSSION
The major aim of this present study was to examine
whether baicalein could protect dopamine neurons from
METH toxic effects. Consistent with previous studies(19),
it was shown that the multiple-dose regiment of METH
significantly decreased the striatal DA concentrations.
We found that baicalein could prevent the METH-induced
depletion of DA in the striatum (Figure 1). Previous
research has shown that METH-induced neurotoxicity to
the DA terminals is caused by the over releasing of DA
and glutamate, which in turn result in enhanced free radicals formation. Blocking NO formation has been reported
to attenuate METH-induced toxic effects(26-27).
We observed that METH caused a significant decrease
in striatal NO concentrations 1 hr after the last injection and NO levels returned to near control values at 24
hrs. This pattern was similar to the observation of NOS
by Halasz et al. after one high dose of METH (7.5 mg/kg,
i.p.)(28). They reported that 0-2 hrs after METH administration, nNOS activity gradually decreased in the striatum,
reaching a maximum decline at 2 hrs but returned to the
control level after 12-24 hrs of the toxic insult. Based on
these findings, we suggest that METH in the initial stage
may diminish NOS enzyme activity, leading to lower NO
formation. The main cause of this outcome was possibly
related to the ATP-depleting effects of METH. Early in
1994, Chan et al. found that a four-dose regimen of METH
caused ATP loss in the striatum(29), and the pattern of ATP
changes were quite similar to our NO results. In addition,
we also observed a delayed increase of NO formation after
3 days of last METH injection which was consistent with
previous studies by Lin et al.(30).
Besides NO production, could ATP-depleting effects
of METH kill DA neurons? When DA neurons lacked
energy support, glutamate may become a toxicant that
facilitated Ca2+ influxes through NMDA receptor into the
presynaptic DA neurons to cause cell death as described in
1994(31). Also, Tung et al. mentioned that D-amphetamine
could deplete both DA and energy in the striatum of rats(32).
This could be another reason of DA neuronal death.
In 2003, Moncada S. et al. mentioned that NO might
be a physiological regulator of cell mitochondrial respiration(33). This finding could somewhat link NO production
with energy depletion together. Since baicalein could
also cause vessel relaxation through inhibiting the protein
kinase C-mediated cellular pathway in vascular smooth
muscle(22,34), it is reasonable to infer that the neuroprotective effect of baicalein against the ATP-depleting effects

of METH can simply come from the increasing of brain
blood flow.
Studies of autoimmune inflammatory diseases of the
central nervous system have identified both astrocytes and
microglia as iNOS-expressing cells. According to these
studies, the sources of NO were more important than the
quantity of NO(35). It has point out that METH-induced
inf lammatory reactions are involved in activating both
microglia and astrocytes. The experiments by Thomas
et al. demonstrated that the NO expressions by microglia were significantly increased at 24, 48, and 72hr after
four times injections of 10 mg/kg METH. On the other
hand, they also observed the depletion of DA after METH
administration was in an inverse ratio with microglial
activation (36). A recently research by Kawasaki et al.
shown that the activations of microglia and astrocytes were
respectively noted on 1 to 3 days and 3 days after repeated
METH treatment (4 mg/kg x 4)(37). And further, inflammatory reactions in activated microglia may be involved
in the molecular pathways of METH-induced neurotoxicity(38). Nevertheless, mechanism for microglial activation
as part of the METH neurotoxic cascade is still unclear.
Our results indicated that the BS groups constantly
maintained NO at a high level from 1hr to 3 days (Figure
2). The over stimulation of NO formation after four-injections of baicalein is an interesting point because in vitro
studies had indicated that baicalein could suppress lipopolysaccharide-induced increase of NO production and the
expression of iNOS in microglia(39-40). The great amount
of NO may play a role in dopaminergic neuroprotection.
Of course, further studies need to be done to differentiate
the source of NO either from astrocytes or microglia cells.
DA levels in baicalein treated mice were slightly
higher than those in the saline control group; we speculate
that baicalein could indirectly increase DA level based on
the report by Hanbauer et al.(41). They demonstrated that
exogenously applied NO evoked [3H]-dopamine release
from cultured synaptosomes. Besides, NO synthesized
by iNOS from astrocyte end-feet improves local blood
flow(42-43). As the study of mitochondria impairment in
dopaminergic neurons showed, raising the concentration
of glucose or mannose could enhance intracellular ATP
synthesis via the citric acid cycle and thus prevent neuronal cell death. Furthermore, sufficient amount of glucose
can also increase DA release and uptake (44-45). Taken
together, baicalein might increase DA level through, 1)
the elevation of NO concentration by increasing iNOS
activity, that leading to vasodilation, and in turn raises
blood f low, glucose concentration, and promoting ATP
synthesis, 2) extra NO production (either from astrocyte or
microglia) might stimulate DA release. These two factors
may contribute to the enhancement of DA level of striatal
tissue in BS group.
In summary, in the present study we demonstrated
that pretreatment with baicalein before METH, could
prevent the suppression of DA levels in the striatum with
the probable involvement of NO and vessel relaxation.
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Baicalein might first stimulate iNOS activity in the glial
cells and finally causing a long-lasting NO production (at
least 3 days). The enhancement of vasodilation in the striatum by large amount of NO and whether baicalein helps
to maintain sufficient ATP synthesis to support normal
neuronal functions will be the subjects for our future work.
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